Aug. 21 at 10:22 AM
$ANAB $TRAX - I tend to look at the combined price of these 2 companies because they are directly linked. Anaptys is the Royalties arm of the two after having spun off the R&D portion of the themselves into First Tracks bio in April 2026.
The combined ceiling appears to be about
$105 currently and the combined COYPT is currently
$157 indicating about a 50% upside. Combined share price sits at ~
$99 at the moment. Lots of cautious optimism ahead as we wait for ongoing revenue from GSK and Vanda collaborations, new pipeline approvals, and resolution to the Tesaro litigation (expected Jan 2027). A breakthrough of that
$105 ceiling would be a positive sign.
LT hold for me. I have owned ANAB since Jan 2018, DCAing and trading along the way so I'm in the black at the moment on the combined value.
https://www.anaptysbio.com/financial-collaborations/our-partnerships/
